Skip to main content

Advertisement

SpringerLink
Log in

Adipocytokines: Emerging therapeutic targets

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Recently, adipocytes have been shown to be recognized as endocrine cells that secrete a variety of bioactive substances known as adipocytokines. Among adipocytokines, adiponectin, a newly found adipose tissue-specific collagen-like protein, has been noted as an important antiatherogenic and antidiabetic protein. The function of adipocytes might be regulated dynamically by nutritional state. Visceral fat accumulation causes dysfunction of adipocytes and results in the development of a variety of metabolic and circulatory diseases through the abnormal secretion of adipocytokines. In this review, the importance of adipocytokines, including adiponectin, is discussed with respect to atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Matsuzawa YM: Pathophysiology and molecular mechanism of visceral fat syndrome: The Japanese case. Diabetes Metab Rev 1997, 13:3–13.

    Article  PubMed  CAS  Google Scholar 

  2. Shimomura I, Funahashi T, Takahashi M, et al.: Enhanced expression of PAI-1 in visceral fat: possible contribution to vascular disease in obesity. Nature Med 1996, 2:1–5.

    Article  Google Scholar 

  3. Lindsay RS, Funahashi T, Hanson RL, et al.: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57–58.

    Article  PubMed  CAS  Google Scholar 

  4. Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein. Circulation 1999, 100:2473–2476.

    PubMed  CAS  Google Scholar 

  5. Okamoto Y, Kihara S, Ouchi N, et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 26:2767–2770.

    Article  Google Scholar 

  6. Kumada M, Kihara S, Sumitsuji S, et al.: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85–89.

    Article  PubMed  CAS  Google Scholar 

  7. Shimomura I, Hammer RE, Ikemoto S, et al.: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999, 401:73–76.

    Article  PubMed  CAS  Google Scholar 

  8. Uysal KT, Wiesblock SM, Mario MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610–614.

    Article  PubMed  CAS  Google Scholar 

  9. Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307–312.

    Article  PubMed  CAS  Google Scholar 

  10. Matsuzawa YM, Funahashi T, Kihara S, Shimomura I: Adioinectin and metabolic syndrome. Arterioscler Thromb Vasc Med 2004, 24:29–34.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sumitomo Hospital, 5-3-20 Nakanoshima, Kita-Ku, 530-0005, Osaka, Japan

    Yuji Matsuzawa MD, PhD

Authors
  1. Yuji Matsuzawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsuzawa, Y. Adipocytokines: Emerging therapeutic targets. Curr Atheroscler Rep 7, 58–62 (2005). https://doi.org/10.1007/s11883-005-0076-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-005-0076-3

Keywords

Search

Navigation